Zacks Investment Research lowered shares of Flexion Therapeutics Inc. (NASDAQ:FLXN) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.

According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “

Several other analysts also recently commented on FLXN. Royal Bank Of Canada reiterated a buy rating on shares of Flexion Therapeutics in a research report on Thursday, June 30th. Lake Street Capital restated a buy rating and set a $38.00 price objective on shares of Flexion Therapeutics in a research report on Tuesday, September 6th. Wells Fargo & Co. restated a buy rating on shares of Flexion Therapeutics in a research report on Thursday, June 30th. BMO Capital Markets restated a buy rating on shares of Flexion Therapeutics in a research report on Tuesday, July 19th. Finally, Vetr upgraded shares of Flexion Therapeutics from a buy rating to a strong-buy rating and set a $15.50 price objective for the company in a research report on Monday, June 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $32.31.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Shares of Flexion Therapeutics (NASDAQ:FLXN) traded up 1.11% during mid-day trading on Tuesday, hitting $19.17. 9,713 shares of the stock traded hands. The firm’s market cap is $527.58 million. The firm’s 50 day moving average price is $17.78 and its 200 day moving average price is $14.84. Flexion Therapeutics has a 12-month low of $7.56 and a 12-month high of $21.71.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Wednesday, August 3rd. The specialty pharmaceutical company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.04. On average, equities research analysts predict that Flexion Therapeutics will post ($2.69) EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Macquarie Group Ltd. purchased a new stake in Flexion Therapeutics during the second quarter valued at about $1,172,000. Royal Bank of Canada boosted its stake in Flexion Therapeutics by 135.6% in the second quarter. Royal Bank of Canada now owns 68,058 shares of the specialty pharmaceutical company’s stock valued at $1,019,000 after buying an additional 39,165 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Flexion Therapeutics by 45.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 28,943 shares of the specialty pharmaceutical company’s stock valued at $434,000 after buying an additional 9,000 shares in the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in Flexion Therapeutics during the second quarter valued at about $176,000. Finally, Highbridge Capital Management LLC purchased a new stake in Flexion Therapeutics during the second quarter valued at about $533,000. 68.27% of the stock is currently owned by institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

5 Day Chart for NASDAQ:FLXN

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.